For more information call (888) LUHS-888.
Patients must be 18 years of age or older and have pathologically confirmed primary adenocarcinoma of the esophagus that involves the mid (up to 25 cm), distal or esophagogastric junction. The cancer may involve the stomach up to 5 cm. Patients must have an endoscopy and a biopsy with the intent to submit tissue for central HER2 testing. The cancer must be stage T1N1-2, T2-3 N0-N2. Patients must have a chest/abdominal/pelvic CT or a whole body PET/CT.
The purpose of this study is to determine whether the addition of the drug trastuzumab to the standard treatment regimen for esophageal cancer can help prevent your cancer from growing back.